The Synthesis of Rotaxane Probes for Magnetic Resonance Imaging (MRI) by Karas, Scott MacGill
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2016 
The Synthesis of Rotaxane Probes for Magnetic Resonance 
Imaging (MRI) 
Scott MacGill Karas 
University of Rhode Island, scott_karas@my.uri.edu 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Karas, Scott MacGill, "The Synthesis of Rotaxane Probes for Magnetic Resonance Imaging (MRI)" (2016). 
Open Access Master's Theses. Paper 962. 
https://digitalcommons.uri.edu/theses/962 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
   
 
 
THE SYNTHESIS OF ROTAXANE PROBES FOR MAGNETIC RESONANCE 
IMAGING (MRI) 
BY 
SCOTT MACGILL KARAS 
 
 
 
 
 
 
THESIS SUBMITTED IN PARTIAL FULLFILMENT OF REQUIREMNTS FOR 
THE DEGREE OF 
MASTER OF SCIENCE  
IN  
CHEMISTRY 
 
 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2016   
   
 
 
MASTER OF SCIENCE THESIS 
OF 
SCOTT MACGILL KARAS 
 
 
 
 
 
 
 APPROVED: 
  Thesis Committee: 
  Major Professor  Brenton DeBoef 
      Mindy Levine 
      Bongsup Cho 
      Nassar H. Zawia 
    DEAN OF THE GRADUATE SCHOOL 
 
 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2016  
   
 
 
ABSTRACT 
Rotaxanes are simple molecules made by an interaction between a host and a 
guest.1 Research has shown that rotaxanes have the capability of exchanging a 
hyperpolarized inert gas atom for use in Magnetic Resonance Imaging (MRI).2 
Currently, MRI contrast is enhanced by the injecting a magnetic gadolinium (III) 
[Gd(III)] ions into the human body prior to the imaging experiment.3 Unfortunately, 
these contrast agents are expensive and toxic; as a result, there is need for a cheaper and 
less toxic imaging agent. Additionally, it would be beneficial to develop targeted 
contrast agents, i.e. macromolecules that bind specific analytes, proteins, or cellular 
receptors within the body. By combining rotaxanes with Hyperpolarized 129Xe 
Chemical Exchange Saturation Transfer (HyperCEST), 129Xe MRI technology should 
be capable of imaging specific areas in the human anatomy, thus facilitating the study 
and diagnosis of diseases or injuries. Currently 129Xe MRI is being used to genertate 
images of the lungs and the brain, but with a synthetic molecule we hope to broaden this 
capability to include high-resolution molecular imaging. 
The manuscript, “Cyclodextrin-based Pseudo-rotaxanes: An Easily 
Conjugatable Scaffold for Hyperpolarized Xenon Magnetic Resonance Imaging 
Biosensors” is the result of our preliminary work to develop a viable molecular probe.  
The manuscript focuses on the development of a new class of xenon-129 MRI contrast 
agents based on rotaxanes of γ-cyclodextrin, and the application of this new technology 
to the synthesis of a potential biosensor for imaging the -amyloid plaques that are 
associated with Alzheimer’s disease.. 
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PREFACE 
 The following work is presented in manuscript format according to the 
guidelines presented by the University of Rhode Island Graduate School. The thesis will 
consist of one manuscript entitled, “Cyclodextrin-based Pseudo-rotaxanes: An Easily 
Conjugatable Scaffold for Hyperpolarized Xenon Magnetic Resonance Imaging 
Biosensors” that has recently been submitted to the Journal of the American Chemical 
Society. 
 Before joining this project, my researched focused was on aromatic C-H 
amination through palladium catalysis. A wide variety of research has been focused on 
the synthesis of aromatic C-N bonds because of their prevalence in pharmaceuticals, 
herbicides, and dyes.4  My work attempted to use oxime esters as electrophilic aminating 
agents to synthesize various aromatic C-N bonds (Scheme 1). After trying a wide variety 
of palladium catalysts and ligands, I was unsuccessful in producing any C-N bonds. 
From there, I moved on to the new project of synthesizing molecular probes to be used 
as potential biosensors. 
 
Scheme 1: Attempted aromatic C-H amination 
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The first potential probe I tried to synthesize involved Folic Acid (FA) because 
of its high binding affinity to folate receptors found in tumors.5 The plan was to bind an 
alkyne to the primary amine of FA (Scheme 2A) to eventually do copper catalyzed 
azide-alkyne cycloaddition (CuAAC) onto a C8 or C10 diazide linker molecule.
6 The 
synthesis of the functionalized FA was a tedious process that ended up not working. 
Next, I tried N-hydroxysuccinimide (NHS) to selectively bind to the γ-carbonyl group. 
NHS activates FA allowing for selective binding of primary amines.7 Like Scheme 2A, 
Scheme 2B was proved to be difficult, and the final product was unable to be observed 
through 1H NMR.  
 
Scheme 2: Folic acid probe. A: Functionalized folic acid. B: Activated folic acid. 
  
Along with FA, Thioflavin-T (ThT) was another molecule I worked with to 
synthesize a potential probe for Alzheimer’s disease. I chose one of several ThT 
derivatives to use as the target moiety. From there I developed three different methods 
to make the ThT probe (Scheme 3). First, I bound a propargyl group to the amine of 
ThT to perform CuAAC to either a C8 or C10 diazide linker. This method proved to be 
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ineffective due to low yields of the propargylated ThT. The second method I tried 
involved the NHS ester of sebacic acid; unfortunately, this reaction didn’t work. The 
final method used sebacoyl chloride as the linker to successfully synthesize the ThT 
probe in high purity and yields. 
 
Scheme 3: ThT probe methods 
 
Subsequent work by me, Ashvin Fernando and others in the group focused on 
the synthesis and NMR analysis of the pseudo-rotaxanes that could be made from the 
compounds that I synthesized.  All of the xenon-129 NMR that is discussed herein was 
performed by our collaborators at the Thunder Bay Regional Research Institute in 
Ontario, Canada. 
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MANUSCRIPT 
 
Cyclodextrin-based Pseudo-rotaxanes: An Easily Conjugatable Scaffold for 
Hyperpolarized Xenon Magnetic Resonance Imaging Biosensors 
 
Abstract 
Hyperpolarized (HP) xenon-129 (Xe) magnetic resonance (MR) imaging has the 
potential to detect picomolar concentrations of molecular biosensors with sub-
millimeter spatial resolution. This high sensitivity and high resolution gives Xe MR 
imaging biosensors the potential to act as a molecular medical imaging modality similar 
to positron emission tomography (PET) but without the use of ionizing radiation. A 
number of challenges have hampered the translation of Xe MR imaging biosensors from 
theoretical and in vitro demonstration to in vivo testing. One of these challenges is the 
difficulty in conjugating the MR active Xe encapsulating cage molecule with an affinity 
tag which binds to the molecule of interest within the body at sufficiently high yields to 
be feasible. In this study we demonstrate that a pseudo-rotaxane based on a γ-
cyclodextrin macrocycle with a 10-carbon axle, is easily synthesized and is detectable 
using HP Xe MR spectroscopy. A pseudo-rotaxane containing Thioflavin T was 
designed and synthesized, as a potential biosensor capable of binding the amyloid fibrils 
that are associated with Alzheimer’s disease (AD). We refer to this potential biosensor 
as Xenon Cage Amyloid Ligand-1 (XCAL-1). 
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Introduction 
Hyperpolarized (HP) xenon-129 based magnetic resonance imaging (MRI) 
biosensors have the potential to become a molecular imaging modality with similar 
sensitivity to positron emission tomography (PET), but with theoretically better spatial 
resolution, no ionizing radiation and lower cost.  HP gas MRI takes advantage of the 
signal enhancement provided by the hyperpolarization of gas, that is, the aligning of the 
spins of a majority of nuclei with an external magnetic field, providing a signal 
enhancement of up to 100,000 times above thermally polarized nuclei.8 HP gas MRI is 
an ideal imaging modality for imaging of the lungs.9 Xe diffuses throughout the whole 
body following inhalation, and because Xe is hydrophobic, it deposits particularly well 
in lipid-rich tissues. High-resolution, three-dimensional images are obtained by 
detecting the HP Xe that is deposited in various fatty tissues, such as the brain.10–12 HP 
Xe atoms cannot, by themselves, be tuned to target particular regions in the body; 
however, targeted HP Xe molecular probes that are capable of binding both biochemical 
receptors and xenon atoms in vivo have been postulated as a way to perform molecular 
imaging, and numerous prototypes have been developed, though targeted HP Xe 
biosensors have yet to be used for imaging in a living animal.   
Like all molecular probes, HP Xe MRI biosensors consist of two functional 
parts, a binding component and a detection component that are joined by a covalent 
tether (Figure 1A).  The binding component is an affinity tag or antibody that binds to 
a specific analyte or biochemical receptor, allowing for the detection and 
characterization of specific biochemical phenomena. The detection component for a HP 
Xe biosensor is usually a supramolecular cage-like structure that can encapsulate a 
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xenon atom. For in vivo imaging, the magnetically active HP Xe can be inhaled by the 
subject and the imaging biosensor can be administered via an injection.  After the 
dissolved Xe gas has circulated through the subject’s body and the targeted biosensor 
has attached to the desired molecular target, the Xe will be reversibly encapsulated by 
the biosensor in a traditional host-guest interaction.  If the reversible encapsulation is 
slow on the NMR time scale, it will produce a unique chemical signal in the 129Xe NMR 
spectrum which can be transformed into a three-dimensional image. 
The Hyperpolarized gas Chemical Exchange Saturation Transfer (HyperCEST) 
pulse sequence takes advantage of the continual diffusion of Xe atoms in and out of a 
Xe-encapsulating cage molecule, and allows for the detection of picomolar 
concentrations of a HP Xe biosensor.13–15   Because the binding of the Xe is reversible, 
but slow on the NMR timescale, the 129Xe spectrum of a biosensor contains two peaks, 
one for unbound Xe and one for the xenon that is encapsulated by the biosensor. By 
exciting the HP Xe atoms inside the supramolecular cage at their unique chemical shift 
offset frequencies, the Xe atoms inside the cage molecules become depolarized. When 
these depolarized Xe atoms exchange with the HP Xe atoms from the pool of dissolved 
Xe atoms, there is a reduction in signal from the pool of dissolved phase Xe atoms 
(Figure 1B). The HyperCEST technique, combined with hyperpolarization of the nuclei, 
provides a theoretical signal enhancement of up to a billion times above thermally 
polarized nuclei.16  
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Figure 1: A/  Schematic of a targeted HP Xe MRI biosensor. B/ Predicted 129Xe spectrum of dissolved HP Xe (orange) 
in the presence of a Xe biosensor (blue) and its detection via HyperCEST. 
Despite the seminal work of Pines and colleagues over two decades ago,14 HP-
Xe MRI biosensor technology has yet to be translated into a clinical imaging technique.  
We recently disclosed the first in vivo images of the MR contrast portion of a xenon MR 
imaging biosensor in a live animal using the non-targeted Xe cage, CB6.17  In our 
opinion, the development of targeted HP Xe MRI biosensors has not been slowed by a 
lack of interest in the techniques or by barriers in MRI technology.  The problem is more 
fundamental:  the supramolecular hosts that encapsulate xenon are difficult to synthesize 
and derivatize, so sufficient quantities of biosensors for in vivo imaging are simply not 
available.  
Herein, we describe the development on a new class of water-soluble HP Xe 
biosensors that use a pseudo-rotaxane to encapsulate HP Xe and can be imaged using a 
HyperCEST pulse sequence.  We have developed a new biosensor based on this scaffold 
that has the potential to image the amyloid fibrils that are associated with Alzheimer’s 
disease (AD), which we call Xenon Cage Amyloid Ligand-1 (XCAL-1). The modular 
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nature of the synthetic scheme should allow for the rapid synthesis of not only XCAL-
1, but a wide variety of biosensors, thus paving the way for numerous clinical 
applications.  
Design of pseudo-rotaxane HP Xe probe 
Our group, as well as others, have tested a number of different xenon hosts 
including cryptophanes,18–21 cucurbiturils,17,22–24 liposomes,25,26 gas vesicles,27 and 
bacterial spores.28 Of these xenon-capturing scaffolds, cryptophane-A has been studied 
the most.  For example, cryptophane-A derivatives have been conjugated to affinity tags 
to bind a wide variety of targets,29–31 such as CD14 cancer cells,32 the cancer-associated 
HER2 receptor, 27 zinc,33 toxic metal ions,34 and the inflammation-marking peripheral 
benzodiazapene receptor (PBR) 35. These reports have not come without a great deal of 
effort.  In one recent report, the Dmochowski group conjugated a cryptophane-A to folic 
acid to yield a potential biosensor for cancer.36 While notable not only for its scientific 
novelty, the tenacity of the research associate who conducted 20 non-linear steps to 
synthesize the final product is remarkable in and of itself. Surely there must be a simpler 
and higher yielding synthesis of a HP-Xe biosensor! 
Until recently, the hollow, ball-shaped molecular cages known as cryptophanes 
appeared to be privileged structures in the field of HP-Xe imaging. Cryptophane-A 
contains a hydrophobic core with a volume of 95 Å3,37 and is capable of reversibly 
binding xenon with a ka of 3 kM
-1, with a residence time of 0.5-8 ms at room temperature 
38. Despite it’s more tube-like structure, cucurbit[6]uril (CB[6]) is also capable of 
binding xenon with a comparable affinity (ka = 200 M
-1),39 but its larger derivatives, 
cucurbit[7]uril (CB[7])and cucurbit[8]uril (CB[8]), do not show any affinity for xenon, 
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as observed by 129Xe NMR. Additionally, ,  and -cyclodextrins (CD), which are 
truncated cone-shaped macrocycles composed of six, seven or eight D-glycopyranoside 
units, have hydrophobic cavities with minimum diameters of 5.3 Å, 6.5 Å and 8.3 Å, 
respectively (Figure 2A). CDs are some of the most commonly used hosts in 
supramolecular chemistry,13a and they would be ideal components of 129Xe biosensors 
because they are non-toxic and water-soluble. Unfortunately, ,  and -CD either fail 
to bind xenon in aqueous media, or the reversible binding has too fast of an exchange 
rate to be observed by 129Xe NMR at room temperature.40b  
We hypothesized that macrocycles that were too large to bind xenon on their 
own, such as the cyclodextrins, could be threaded with long alkyl chains to create 
rotaxane-type complexes that were capable of forming a ternary complex with xenon 
(Figure 2B).13c Rotaxanes are well-known supramolecular species composed of a 
molecular axle that is threaded through a tube-shaped host, creating a non-covalently 
bound structure.  In order to serve as a molecular probe, the inner diameter of the 
rotaxane’s macrocycle must be large enough to fit both the molecular axle and a xenon 
atom in its hydrophobic core. However, a macrocycle that is too large would not be 
detectable using HyperCEST because the xenon would exchange in and out of the host 
at a rate that is too high to support HyperCEST detection. Prior to this work the only 
precedent for the formation of this kind of ternary complex with xenon was reported by 
Cohen, who showed that a CB6 derivative could simultaneously bind hexane and 
xenon.40 Consequently, we designed three classes of pseudo-rotaxanes to determine 
their potential as the imaging component of HP-Xe biosensors: CB-based pseudo-
rotaxanes, pillararene-based pseudo-rotaxanes, and CD-based pseudo-rotaxanes.   
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Figure 2: A/ Electrostatic potential maps and chemical structures of cucurbiturils and cyclodextrins. B/ Proposed 
binding of xenon via formation of a ternary complex. 
 
In addition to the novelty of the ternary xenon complexes, the design shown in 
Figure 2B could also expedite the development of a wide variety of biosensors because 
they would not be synthesized by covalently tethering the affinity tag to the xenon host; 
rather, the affinity tag would be conjugated to the axle of the rotaxane, which is 
presumably a straightforward process, and the tethering of the affinity tag to the 
macrocycle would then be accomplished via classic supramolecular chemistry relying 
primarily on hydrophobic interactions, which, coincidentally, are the same forces that 
are required for efficient xenon binding. For these preliminary studies, we defined two 
criteria for success: firstly, the molecule had to be readily synthesized and conjugatable.  
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Secondly, the molecule had to be MR detectable by displaying a HyperCEST effect.  
Towards the first goal, we found that pillararenes were relatively easy to synthesize and 
CB and CD macrocycles are both commercially available.  Each of the host molecules 
were threaded with five, eight and ten-carbon molecular threads that contained terminal 
ethylimidazolium groups, which served to enhance the water solubility of the greasy 
alkanes and enabled facile detection by mass spectrometry (Scheme 1).  Furthermore, 
one can easily imagine methods to create similar moieties that were attached to affinity 
tags.  In all cases studied, the rapid formation of threaded complexes was observed by 
NMR, though most cases showed rapid host-guest exchange on the NMR time scale.  
Subsequent analysis by 129Xe NMR quickly identified the promising scaffolds that 
combined the desired attributes of facile synthesis with MR detectability via 
HyperCEST. 
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Scheme 4: Synthesis of various guests. A/ Synthesis of the C10 diethylimidazolium bar (1) and its incorporation into 
γ-CD to form a pseudo-rotaxane.  B/ Other bars tested in pseudo-rotaxanes: C5 diethylimdazolium bar (2), C8 
diethylimdazolium bar (3), C8 diazide bar (4) and C8 diazide bar (5). 
 
For the HP-Xe studies, we used a custom-built fritted phantom inside of a 
custom dual tuned 1H/129Xe radiofrequency (RF) coil to acquire all free induction decay 
(FID) spectra (Figure 3). Cage molecules, dissolved in water and/or DMSO, were placed 
inside the fritted phantom, and HP 129Xe was introduced below the fritted phantom 
which created microbubbles that bubbled vertically through the sample. A series of 
saturation pre-pulses at a variety of chemical shift offsets were loaded into the user 
interface software of the GE Achieva 3T MR scanner. Spectra with different saturation 
pre-pulses were acquired approximately every six seconds. 
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Figure 3: Schematic of experimental setup. 10 mM of γ-cyclodextrin with a C10 diethylimidazolium bar (1γ-CD) 
dissolved in water was placed inside of a fritted phantom and placed inside an NMR RF coil. Hyperpolarized xenon 
was introduced into the phantom via a glass frit which produced microbubbles that dissolved in the solution. The HP-
Xe atoms diffused in and out of the CD cage. An RF saturation pulse was applied at the Xe-CD chemical shift offset 
frequency depolarizing the 129Xe within the CD. The depolarized 129Xe diffused out of the CD and was replaced by 
a HP-Xe atom. This resulted in a reduction in the pool of HP Xe in solution thereby depleting the NMR signal which 
indicates the presence of the probe molecule. The absence of a Xe imaging probe in the solution would result in no 
depletion of the dissolved phase Xe signal. 
 
Discovery of pseudo-rotaxane HP Xe probes 
Our initial studies commenced with the analysis of cucurbiturils, as we have 
previously had success using the most common member of this family of macrocycles, 
CB6, in HyperCEST studies.  As expected, irradiation at +128 ppm (relative to the peak 
corresponding to dissolved xenon) produced a 67% depletion, thus confirming that our 
experimental method was reliable.  Various threaded complexes of CB6, CB7 and CB8 
were then synthesized (see Supporting Information) and subjected to the same 
HyperCEST protocol.  Unfortunately, none of the pseudo-rotaxanes could be detected 
by HyperCEST, indicating that there is not sufficient space in the cavity of the 
supramolecular complex (likely true for complexes like 1CB6) or that that xenon 
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exchanges too rapidly in and out of the complex to be detected (possibly true for larger 
complexes like 1CB8). 
Two different pillarene structures were also tested (see Supporting Information 
for structures), but both suffered from poor water solubility.  Consequently, organic co-
solvents or non-ionic diazide bars (Scheme 4) had to be employed.  All pillararene-
derived threaded complexes failed to produce a HyperCEST signal.  This was surprising 
because  pillararene-based pseudo-rotaxane reported to be was capable of binding 
xenon.41 We attempted to further these studies by applying HyperCEST saturation 
pulses and acquiring a HyperCEST depletion spectrum, but we were unable to observe 
a HyperCEST effect in pseudo-rotaxanes based on the pillararene macrocycle.  We were 
neither able to detect the presence of a peak corresponding to a xenon-pillararene 
complex, nor a HyperCEST effect.  
 Gratifyingly, we found that cycodextrin-based pseudo-rotaxanes can reversibly 
encapsulate xenon and be detected by 129Xe magnetic resonance spectroscopy.  A 
HyperCEST depletion of 30% for the pseudo-rotaxane formed by mixing α-cyclodextrin 
with the C5 diethylimidazolium bar (2-CD), and 52% for γ-cyclodextrin pseudo-
rotaxanes with the C10 diethylimidazolium bar threaded through the cavity (1γ-CD). 
The maximum HyperCEST depletion for all three cyclodextrin-based rotaxanes 
occurred at approximately +128 ppm from the Xe gas phase signal.  HyperCEST 
depletion spectra for 1γ-CD are shown in Figure 4.  Importantly the HyperCEST 
depletion for (1γ-CD) was comparable to that of CB6, a xenon cage that we have 
recently shown to be amenable to in vivo HP Xe MRI. 
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The data shown in Table 1 and Figure 4 were obtained using a Phillips Achieva 
3T clinical whole-body MR scanner, which proves significant advantages over 
conventional NMR spectrometers, namely the ability to perform whole-body imaging 
experiments.  Unfortunately, these advantages come with some trade-offs, specifically 
the ability to acquire HyperCEST depletion spectra with a Lorenzian fit line, such as in 
the data processed for cryptophane and cucurbituril agents as demonstrated by the 
Schroeder and Dmochowski groups using high-field, high-resolution NMR 
spectrometers.42–45  However, the use of a clinical scanner  bodes well for eventual 
clinical translation of our techniques in in vivo experiments, which we recently 
demonstrated using a non-targeted 129Xe contrast agent.17 
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Table 1:  HyperCEST data for pseudo-rotaxanes 
 
Pseudo-rotaxane  
     (macrocycle + bar) 
% 
Depletion a 
 
(ppm)a 
cucurbit[6]uril   
     + none 67% +128 
     + C8 diethylimidazolium bar (3) 0% - 
     + C10 diethylimidazolium bar (1) 0% - 
cucurbit[7]uril   
     + none 0% - 
     + C8 diethylimidazolium bar (3) 0% - 
cucurbit[8]uril   
     + none 0% - 
     + C8 diethylimidazolium bar (3) 0% - 
     + C10 diethylimidazolium bar  (1) 0% - 
decamethyl-pillar[5]arene   
     + none a 0% - 
     + C8 diethylimidazolium bar (3) b 0% - 
decabromoethyl-pillar[5]arene   
     + none c 0% - 
     + C8 diazide bar (4) c 0% - 
     + C10 diazide bar (5) c 0% - 
-cyclodextrin   
     + none 0% - 
     + C5 diethylimidazolium bar (2) 30% +132  
     + C8 diethylimidazolium bar (3) 0% - 
     + C10 diethylimidazolium bar (1) 0% - 
-cyclodextrin   
     + none 0% - 
     + C5 diethylimidazolium bar (2) 0% - 
     + C8 diethylimidazolium bar (3) 0% - 
     + C10 diethylimidazolium bar (1) 0% - 
-cyclodextrin   
     + none 0% - 
     + C5 diethylimidazolium bar (2) 0% - 
     + C8 diethylimidazolium bar (3) 43% +128  
     + C10 diethylimidazolium bar (1) 50% +128  
a Samples (2 mL, 10 mM) were dissolved in water, 1D 129Xe spectrum were initially recorded and then a series of 
HyperCEST spectra were sequentially recorded using a series of  off resonance pulses varying by 5 ppm. b Performed 
in H2O/DMSO.  c Performed in CHCl3. 
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Figure 4: FID and HyperCEST depletion spectra of γ-cyclodextrin with the C10 diethylimidazolium bar (1γ-CD).  
Free Induction Decay (FID) spectra of 10 mM γ-cyclodextrin with a 10-carbon ethyl imidazole bar following off-
resonance (A) (+255 ppm) and on-resonance (+128 ppm) HyperCEST pulses (B). HyperCEST depletion z-spectrum 
(C) of 10 mM γ-cyclodextrin with the C10 diethylimidazolium bar (1γ-CD). Each data point indicates the 
HyperCEST depletion when the molecule is irradiated with a HyperCEST pulse at a given chemical shift offset. A 
maximum HyperCEST depletion of 52% occurs. 
 
1H NMR also confirms the formation of the ternary pseudo-rotaxane-xenon 
complex [(Xe·1)γ-CD Figure 5].  Formation of the pseudo-rotaxane with -
cyclodextrin and 1 can be easily monitored by an upfield shift in the triplet 
corresponding to the proton attached to the C3 position in the in the cyclodextrin.  This 
proton is positioned on the interior of the macrocycle, so it is shielded when the pseudo-
rotaxane forms.  Subsequent binding of xenon further shifts the C3-H peak upfield, 
indicating that the xenon also binds to the interior of the macrocyclic host.   
NMR titration studies were performed to assess the nature of the host:guest 
interaction for 1γ-CD.46 An association constant of 8.8 x 102 M-1 for the 1:1 host:guest 
complex was measured.  (see Supporting Information for details.)  Despite this modest 
affinity, the formation of both the binary (1γ-CD) and ternary [(Xe·1)γ-CD] 
complexes is favorable and detectable by 1H and 129Xe NMR.14 
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Figure 5: 1H NMR evidence for the formation of the ternary complex.  A/ 1H NMR spectrum of γ-cyclodextrin.   B/ 
1H NMR spectrum after addition of 1 equiv of 1.  C/ 1H NMR spectrum after addition of 1.5 atm xenon. 
 
Application to the synthesis of XCAL-1 
To demonstrate the utility of this new class of xenon-binding agents for the 
synthesis of targeted biosensors, we synthesized a potential molecular probe using 
Thioflavin T (ThT).  ThT is a fluorescent dye that binds to the -amyloid plaques that 
are associated with Alzheimer’s disease (AD).47 Using HP Xe biosensors like XCAL-
1, we envision potential clinical applications for studying the progression of AD or the 
efficacy of treatments for it (Scheme 5). 
The synthesis of the biosensor involves a simple acylation, followed by the 
formation of the pseudo-rotaxane.  Both steps are nearly quantitative.  As before, 
formation of the 1:1 complex was confirmed by 1H NMR studies, and the association 
constant for the pseudo-rotaxane was determined to be 2.0 x 104 M-1.  Thus far, we have 
synthesized XCAL-1 on a scale of hundreds of milligrams, but the reactions are simple 
Xe
R R
Xe
R R
g-CD
R R
g-CD C3-H
A/
B/
C/
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and high-yielding.  There is no reason to believe that biosensors like XCAL-1 could not 
be synthesized on a gram scale, or larger, thus paving the way for in vivo imaging 
studies. 
 
Scheme 5: Facile synthesis of the potential biosensor, XCAL-1. 
Summary 
In conclusion, we have discovered a novel method for synthesizing potential HP 
Xe biosensors by using pseudo-rotaxane structures of -CD.  These supramolecular 
complexes form a novel ternary structure in the presence of HP Xe which can be 
detected via 129Xe MR spectroscopy and imaging experiments.  Future work by our 
collaborative team will involve ex vivo and in vivo analysis of the XCAL-1 probe for 
imaging -amyloid plaques.  Furthermore, the ease of synthesis of these pseudo-
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rotaxane probes should allow for the rapid development of numerous other HP Xe 
biosensors. 
Experimental Methods 
 Nuclear Magnetic Resonance (NMR) HyperCEST Detection.  Natural abundant 
129Xe gas was polarized to 26-30% using a Xemed polarizer (Xemed, Durham, NH, 
USA). 1.0 mL of sample was drawn into the glass frit cell using a syringe.  The cell was 
then inserted into a custom RF coil tuned to the Larmor frequency of 129Xe (35.33 MHz) 
at 3T, where HP 129Xe gas was introduced to the vessel from the Tedlar bag in the 
pressure chamber which was pressurized at 35 kPa above atmosphere.  The solution was 
mixed with HP 129Xe gas as it passed through the fine fritted disc and produced several 
microbubbles, which continuously dissolved into solution and exited the vessel through 
the outflow tube. The concentration of 129Xe at any point during the experiment was 
between 1-10 mM. A Philips Achieva 3T clinical scanner was used to collect all NMR 
spectra.   The RF pulse length was determined with the use of the Ref B1, a parameter 
of Philips MR scanners.  The pulse length and flip angle were used to calculate the 
amplitude of the RF pulse and field strength. In this study, the B1 field strength was 
determined by the scanner to be 15.9 µT. In the acquisition of NMR spectra, a pulsed 
saturation pre-pulse train consisting of 96- 20 ms 3-lobe sinc pulses with 0 ms pulse 
intervals was applied at various chemical shift offsets. Free induction decay (FID) 
spectra were acquired at various chemical shift frequency offsets, approximately 5 ppm 
apart. Each FID spectra was acquired approximately 6 seconds apart. Off-resonance FID 
spectra were obtained quarterly in this series and acquired with a saturation pre-pulse at 
+271 ppm off resonance from the gas phase peak. A HyperCEST depletion spectrum 
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was collected for each sample (See Supplemental Information) by measuring 
HyperCEST depletion at various frequency offsets from the Xe gas phase peak.  A 
minimum of 3 spectra were obtained at each of the various chemical shifts and a plot of 
the mean signal depletion as a function of the frequency of the chemical shift offset (z-
spectrum) was produced.  The mean signal-to-noise ratio (SNR) obtained from all 
control spectra for individual samples were used in the measurement of signal 
depletion.  The SNR for each spectrum was calculated using MATLAB (MathWorks, 
Natick, MA, USA).  To measure signal depletion, the mean HyperCEST saturation 
spectrum SNR was subtracted from the mean control spectrum SNR.  This difference 
was then divided by the mean control spectrum SNR to produce the signal depletion by 
the HyperCEST effect. 
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APPENDIX 
Background Information 
Nuclear magnetic resonance imaging (MRI) is a common tool used for 
visualizing deep tissue  in real time in vivo.2,48 MRI is the detection of protons found in 
the body through the alignment of their nuclei with the magnetic field to produce a  
signal.49 This method has allowed medical professionals to study injuries in deep tissue 
such as torn ligaments or large tumors.48 Although MRI is only capable of imaging 
molecules with a concentration of 10-3 to 10-5 moles per liter while the molecular 
receptors or genes that are often responsible for disease have a concentration of 10-6  to 
10-12 moles per liter.2 The use of contrasting agents has helped increase the spatial and 
temporal resolution of the MRI. A popular contrast agent currently being used is 
gadolinium (III) (Gd(III)). A drawback with Gd(III) is its very expensive, because it is 
a rare earth metal mined in only six countries, and if unligated, it is toxic to the patient 
being administered.  
 
Figure 6: Example of a Gadolinium (III) Chelate [Gd(DTPA)(H2O)]2- 
The development of cheaper and less toxic contrast agents have been researched 
by multiple groups.50 One of the emerging methods in this field  is the use of 
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hyperpolarized (HP) noble gases, Helium-3 (3He) and Xenon-129 (129Xe). Both of these 
atoms are viable alternatives to Gd(III) because they are non-toxic and easily removed 
from the body naturally. 3He is only used for imaging the lungs but not for deep tissue 
because 3He isn't lipophilic. 129Xe, on the other hand, diffuses throughout all regions of 
the body, so it is capable of deep tissue imaging. It has a long resonance relaxation time 
that increases the sensitivity of 129Xe NMR by five orders of magnitude.41 Unlike 
Gd(III), 129Xe has a low binding affinity to proteins in the body; as a result, it is much 
less toxic.2,41,48,51 
The hyperpolarization (HP) of 3He or 129Xe aligns nearly all of the nuclei with 
the NMR or MRI magnet; as a result, increasing the sensitivity of the instrument.52 
Without HP, the magnet can only align a small number of the nuclei.51 A noble gas 
becomes polarized through a process called spin-exchange optical pumping (SEOP).53 
SEOP is the transfer of electron spin through the collision of polarized alkali-metal 
atoms to noble gas atoms.54 A In small amounts, 3He and 129Xe can have a 95% and 
65% degree of polarization, respectively.55 Currently hyperpolarized 129Xe MRI has 
been used in vivo to image the distribution of 129Xe in lungs and brain.53  
 
Figure 7: Example of 129Xe Biosensor 
With HP 129Xe and MRI capabilities, the option to detect specific tumors, 
molecules, and proteins are available with the help of a 129Xe biosensor. The biosensor 
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consists of a cage molecule, linker, and targeting moiety (Figure 6).16,52 The 129Xe will 
exchange quickly in and out of the cage to produce a defined NMR signal different to 
that of free HP 129Xe.14,52,56,57 The caged molecules can be functionalized to bind to 
specific biological receptor.14 Previously, cryptophane-A has been functionalized and 
shown exchanging HP 129Xe (Figure 8).16,52 A 129Xe biosensor allows for the study and 
diagnosis of various biochemical phenomena. 
 
Figure 8: Cryptophane-A with a linker and target moiety having 129Xe being encapsulated. 
The synthesis of rotaxane probes can assist in broadening the capabilities of 
129Xe biosensors. Rotaxanes are in a category of mechanically interlocking molecules 
(MIM).58 They consist of a cyclic molecule, host, and a linear molecule, guest, bound 
together by noncovalent forces forming a host-guest relationship.58 Some common hosts 
are cucurbit[n]urils, pillar[n]enes, and cyclodextrins with each varying in size, shape, 
and capability. Biological applications of rotaxanes include optical bioimaging, drug 
delivery, and cell transport agents.59 Rotaxanes  can form a ternary complex with HP 
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129Xe to create a molecular biosensor.  We are capable to detect, in small amounts, the 
129Xe biosensors in the body using Hyperpolarized 129Xe Chemical Exchange Saturation 
Transfer (HyperCEST).19 Right now we are trying to synthesize a Folic Acid probe to 
bind to cancer tumors and a Thioflavin-T probe to image cells found in Alzheimer’s 
disease.  
Thioflavin-T Molecular Probe 
Thioflavin-T (ThT) is a fluorescent molecule with a high binding affinity to beta-
amyloid (Aβ) plaques used to diagnose Alzheimer’s Disease (AD), a type of dementia, 
in the brain.60–62 Amyloid plaques are developed from amyloid precursor proteins 
(APPs), also known as senile plaques, found exclusively in AD patients. Aβ plaques are 
a type of amyloidosis, a disease, caused by the misfolding of peptide or protein that is 
unable to remain in its natural state.61,63 Along with AD, amyloidosis has been 
associated with Parkinson’s Disease, type-II diabetes, and cataracts.61,63,64 As an 
individual ages, amyloid plaques build up inside neurons and blood vessels in the brain 
to reduce the functionality of the brain.64 In order to diagnose AD, physicians need to 
detect the presence of Aβ along with any cognitive deterioration.60 Pharmaceutical 
companies have developed ThT derivatives to be used in vitro allowing for the 
identification and quantification of Aβ.65 Once the ThT binds to Aβ, ThT fluoresces 
with an excitation at 440nm and with emission at 490nm. Unbound ThT has a very low 
fluorescence with an blue-shifted excitation at 350nm and emission at 440nm.63 
 Using the capability to synthesize various ThT derivations, we wanted to 
synthesize a molecular probe, as stated earlier, to image Aβ using MRI. We chose 4-
aminobenzothiazole because it is the easiest derivative to synthesize (Scheme 1). Based 
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on the determined inclusion complexes, 8-carbon and 10-carbon alkyl guests were 
chosen to make up the core of our molecular probe.  
 The first approach was to bind ThT (compound 7) to the alkyl chain by an azide-
alkyne  “click” reaction (Scheme 6)66 or through a nucleophilic acyl substitution 
(Scheme 7).67, 68 The “click” reaction route required the synthesis of a propargylated 
ThT (10) and a diazido alkyl chain (4 and 5).  Unfortunately the “click” reaction was 
unable to be purified or confirmed by NMR; as a result, the acyl substitution (Scheme 
4) was attempted using ThT with sebacoyl chloride (route 1), and disuccinimidyl 
sebacate (9, route 2). Synthetic route 1 was able to produce compound 8 with a yield of 
98%. Route 2 produced no product, only starting material. With the bar for the rotaxane 
(8) in hand, the next step was to perform binding studies with γ-cyclodextrin and 129Xe 
to see if we have successfully created a new pseudo-rotaxane molecular probe. 
 
Scheme 6: Synthetic route for propargylated thioflavin-T reaction and diazido alkyl chain. 
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Scheme 7: Synthetic routes for the thioflavin-T probe. 
Folic Acid Molecular Probe 
Folic acid (FA) was chosen to make a biosensor due to its high binding affinity 
to folate receptors (FR) which are upregulated in many tumors, particularly ovary, lung, 
breast, kidney, brain, endometrium, and colon cancers.5 Currently, FA conjugated drugs 
are being used as cancer treatments by binding to the FR located on cancer tumors. FA 
is water soluble and naturally forming, which makes it cheap, readily available, and 
applicable to a wide range of cancer tumors.5 Having a probe that specifically binds to 
one of these tumors would allow researchers and physicians to study and treat these 
diseases more efficiently. 
Using the same approach as the ThT molecular probe, we wanted to bind FA to 
an alkyl chain by functionalizing FA. We have made several unsuccessful attempts to 
bind dibromopropanyl chloride (DBPC) to the primary amine in order to perform a 
“click” reaction to either compound 4 or 5 (Scheme 8).69,6 The next approach would be 
to perform a coupling reaction to activate γ-carboxylic acid of FA with N-
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hydroxysuccinimide and to react this activated ester with 1,10-diaminodecane to form 
a molecular thread containing FA on both ends (Scheme 9).67 
The preliminary development of a ThT probe was successful. After performing 
the binding studies, we determined a pseudo-rotaxane, not a rotaxane, was formed. The 
pseudo-rotaxane allows for the guest molecule to slip in and out of the host molecule. 
Our probe can be altered to make a rotaxane by conjugating a large end cap to one side 
of the guest molecule. This should lock the ThT probe in place not allowing any 
exchange between the host and guest. When the FA probe is synthesized, there might 
be an issue of threading the probe into a host molecule due to the size of the FA. If there 
are complications threading the probe, the FAs will need to be bound in situ with the 
alkyl chain and host molecules. 
 
Scheme 8: Synthetic route using functionalized folic acid. 
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Scheme 9: Synthetic route using activated folic acid. 
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Experimental 
 Known and novel compounds were synthesized according to the following 
procedures. 
Reagents 
Substrates, including methyl 4-amino-3-methoxybenzoate ,4-(hydroxymethyl)-2 
methoxyphenol, dibromoethane, 4-hydroxy benzaldehyde, tris(2-aminoethyl)amine, 
iron(iii)perchlorate hydrate , phsophorous pentoxide, glyoxal, urea, p-tertbutyl phenol, 
1,4-dimethoxybenzene, 1,4-bis(2-hydroxy)benzene, 1-ethylimidazole, 1,8-
dibromooctane, 1,10-Dibromodecane, 1,5-dibromopentane, cucurbit[6]uril, 
cucurbit[7]uril, cucurbit[8]uril, sebacoyl chloride, polyphosphoric acid, 2-
aminothiophenol, 4-aminobenzoic acid, sodium azide, alpha-cyclodextrin, beta-
cyclodextrin and gamma-cyclodextrin were purchased from Sigma-Aldrich, Fisher 
Scientific, and TCI chemicals. Flash chromatography was performed using a Teledyne-
Isco CombiFlash Rf with Redisep Gold silica cartridges. All reagents were stored under 
an inert atmosphere before use. All reaction was performed under N2 atmosphere if not 
mentioned. 
Instrumentation  
NMR spectra were obtained using a Bruker Avance 300 MHz spectrometer and a Bruker 
Avance 400 MHz spectrometer. Low resolution mass spectrometry was performed 
using a Shimadzu LRMS-2020. 
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Synthesis of C10 diethylimidazolium bar, 1 
 
1-Ethylimidazole (1.94 mL, 20 mmol) and 1, 10-dibromodecane (1.79 mL, 8 mmol) 
were dissolved in toluene (15 mL) and refluxed for 12 hours. Once complete, the toluene 
was poured out while the crude product remained in the flask. The crude product was 
washed with diethyl ether (3 x 20mL) then dried under vacuum until a white solid 
product formed (3.78 g, 56% yield). Spectral data matched the reported values.70 
1H NMR (400 MHz, D2O) δ 8.80 (s, J = 1.7 Hz, 2H), 7.51 (d, J = 9.1, 1.9 Hz, 4H), 4.3 
– 4.12 (m, 8H), 1.88 (m, J = 7.1 Hz, 4H), 1.52 (t, J = 7.4 Hz, 6H), 1.37 – 1.21 (m, 12H). 
 
 13C NMR (101 MHz, D2O) δ 134.75, 122.26, 121.95, 49.57, 44.80, 29.14, 28.32, 
27.96, 25.29, 14.50. 
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Spectrum 1 – 1H NMR of Compound 1 
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Spectrum 2 – 13C NMR of Compound 1 
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Synthesis of C5 diethylimidazolium bar,  2 
 
1-ethylimidazole (1.9 mL, 20 mmol) and 1,5-dibromooctane (1.1 mL, 8 mmol) were 
dissolved in toluene (50 mL) and refluxed overnight. The toluene was poured out while 
the crude product was left in the flask. The crude product was washed with diethyl ether 
(3 x 50mL) then dried by vacuum to form white solid product (2.5 g, 48% yield). 
Spectral data matched the reported values.71 
1H NMR (300 MHz, D2O) δ 8.74 (s, 2H), 7.45 (d, J = 9.8, 1.9 Hz, 4H), 4.22 – 4.11 (m, 
8H), 1.92 – 1.83 (m, 4H), 1.44 (t, J = 7.4 Hz, 6H), 1.30 – 1.24 (m, 2H). 
 
13C NMR (101 MHz, D2O) δ 134.86, 122.21, 122.03, 49.19, 44.86, 28.71, 22.24, 14.51. 
 
LRMS ESI (m/z): [M+] calculated for C15H26N4Br2 131.11, observed 131.11. 
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Spectrum 3 – 1H NMR of Compound 2 
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Spectrum 4 – 13C NMR of Compound 2  
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Synthesis of C8 diethylimidazolium bar, 3 
 
1-Ethylimidazole (1.06 mL, 11 mmol) and 1, 8-dibromooctane (808.7 µL, 4.4 mmol) 
were dissolved in toluene (15 mL) and refluxed for 12 hrs. Once complete, the toluene 
was poured out while the crude product remained in the flask. The crude product was 
washed with diethyl ether (3 x 20 mL) then dried under vacuum until a white solid 
product formed (1.266 g, 38% yield)Spectral data matched the reported values70.  
1H NMR (400 MHz, D2O) δ 8.74 (s, 2H), 7.45 (d, J = 8.1, 1.9 Hz, 4H), 4.25 – 4.07 (m, 
8H), 1.88 – 1.75 (m, 4H), 1.45 (t, J = 7.3 Hz, 6H), 1.29 – 1.20 (m, 8H). 
 
13C NMR (101 MHz, D2O) δ 134.79, 122.29, 121.99, 49.58, 44.86, 29.17, 27.85, 25.26, 
14.57. 
 
  
   
36 
 
 
Spectrum 5 – 1H NMR of Compound 3  
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Spectrum 6 – 13C NMR of Compound 3  
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Synthesis of C8 diazide bar, 4 
 
1,8–dibromooctane (1.84 g, 10 mmol) and sodium azide (1.95 g, 30 mmol) were 
dissolved in DMF (15 mL). The reaction was stirred at 60 °C for 24 hrs. Once complete, 
water (300 mL) was added then extracted with methylene chloride (3 x 100 mL). The 
organic layers were combined and dried with sodium sulfate. The sodium sulfate was 
filtered out and the solvent was removed under vacuum. The crude product was purified 
using column chromatography (hexane:ethyl acetate; 10:1) to produce a clear oil (1.3 g, 
66% yield) Spectral data matches the reported values.69  
1H NMR (400 MHz, CDCl3) δ 3.26 (t, J = 6.9 Hz, 4H), 1.59 (p, J = 7.0 Hz, 4H), 1.45 
– 1.27 (m, 8H).  
 
13C NMR (101 MHz, CDCl3) δ 51.44, 29.00, 28.80, 26.61. 
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Spectrum 7 – 1H NMR of Compound 4 
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Spectrum 8 – 13C NMR of Compound 4 
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Synthesis of C10 diazide bar, 5 
 
1,10–dibromodecane (2.24 mL, 10 mmol) and sodium azide (1.95 g, 30 mmol) were 
dissolved in DMF (15 mL). The reaction was stirred at 60 °C for 24 hrs. Once complete, 
water (300 mL) was added then extracted with methylene chloride (3 x 100 mL). The 
organic layers were combined and dried with sodium sulfate. The sodium sulfate was 
filtered out and the solvent was removed under vacuum. The crude product was purified 
using column chromatography (hexane:ethyl acetate; 10:1) to produce a clear oil (1.38 
g, 62% yield). Spectral data matched reported values.72  
1H NMR (400 MHz, CDCl3) δ 3.25 (t, J = 6.9 Hz, 4H), 1.65 – 1.53 (m, 4H), 1.43 – 
1.22 (m, 12H).  
 
13C NMR (101 MHz, CDCl3) δ 51.47, 29.35, 29.10, 28.83, 26.69. 
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Spectrum 9 – 1H NMR of Compound 5 
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Spectrum 10 – 13C NMR of Compound 5 
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Synthesis of decadimethoxy-pillar[5]arene 
 
To a solution of 1,4-dimethoxybenzene (1.38 g, 10mmol) in 1,2-dichloroethane (20 mL) 
was added paraformaldehyde (0.93 g, 30 mmol). Then, boron trifluoride diethyl etherate 
([BF3O(C2H5)2], 1.25 mL, 10 mmol) was added to the solution, and the mixture was 
stirred at 30 °C for 30 min. The solution was poured into ethanol (50 mL), and the 
resulting precipitate was collected by filtration. The obtained solid was recrystallized 
from acetone to give decamethyl pillar[5]arene as an off white solid (0.83 g, 71% yield). 
Spectral data matched reported values.73 
 1H NMR (400 MHz, CDCl3) δ 6.91 (s, J = 14.1 Hz, 10H), 3.79 (s, J = 12.6 Hz, 10H), 
3.76 (s, J = 13.8 Hz, 30H).  
 
13C NMR (75 MHz, CDCl3) δ 150.27, 128.18, 113.17, 55.32, 40.65, 29.18. 
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Spectrum 11 – 1H NMR of decmethyl-pillar[5]arene  
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Spectrum 12 – 13C NMR of decamethyl-pill[5]arene  
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Synthesis of decadibromoethoxy-pillar[5]arene 
 
A solution of 1,4-bis(2-hydroxyethoxy)benzene (2.5 g , 12.6 mmol) and 
triphenylphosphine (7.8 g, 30 mmol) in dry acetonitrile (62.5 mL) was cooled with an 
ice bath. Under vigorous stirring, carbon tetrabromide (9.9 g, 30 mmol) was slowly 
added. The mixture was stirred at room temperature for 4 hrs. Cold water (50 mL) was 
added to the reaction mixture, producing a white precipitate. The precipitate was 
collected, washed with methanol/water (3:2, 3 × 25 mL), recrystallized from methanol, 
and dried under vacuum to afford the product as white crystals (1.99 g, 49% yield). 
Spectral data matched the reported values.74 
1H NMR (300 MHz, CDCl3) δ 6.88 (s, 4H), 4.27 (t, J = 6.3 Hz, 4H), 3.64 (t, J = 6.3 
Hz, 4H). 
 
13C NMR (101 MHz, CDCl3) δ 152.82, 116.09, 68.71, 29.28.  
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A solution of 1,4-bis(2-bromoethoxy)benzene (3.37 g, 11.5 mmol) and 
paraformaldehyde (0.349 g, 11.5 mmol) in 1,2-dichloroethane (30 mL) was cooled with 
ice bath. Boron trifluoride etherate (3.26 g, 23.0 mmol) was added to the solution and 
the mixture was stirred at room temperature for 1 hour. The reaction mixture was then 
washed with water (2 × 30 mL) and dried with Na2SO4. The solvent was evaporated to 
provide a crude product, which was purified by Combi-flash chromatography (eluent: 
petroleum ether/ethyl acetate, 100:1) to afford a white solid (4.83 g, 25% yield). Spectral 
data matched reported values.74  
1H NMR (300 MHz, CDCl3) δ 6.92 (s, 10H), 4.24 (t, J = 5.7 Hz, 20H), 3.85 (s, 10H), 
3.64 (t, J = 5.7 Hz, 20H).  
 
13C NMR (101 MHz, CDCl3) δ 149.67, 129.03, 116.10, 68.99, 30.71, 29.40. 
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Spectrum 13 – 1H NMR of 1,4-bis(2-bromoethoxy)benzene  
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Spectrum 14 – 13C NMR of 1,4-bis(2-bromoethoxy)benzene   
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Spectrum 15 – 1H NMR of decadibromoethoxy-pillar[5]arene   
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Spectrum 16 – 13C NMR of NMR of decadibromoethoxy-pillar[5]arene   
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Synthesis of Thioflavin-T (4-aminobenzothiazole, 7) 
 
4-Aminobenzoic acid (0.960 g, 7 mmol), 2-aminothiophenol (0.790 mL, 7 mmol), and 
polyphosphoric acid (7.45 g, 87.5 mmol) were placed in a flask. The mixture was heated 
to 200°C for 4 hours. Once complete, the mixture was allowed to cool, and then poured 
into 200 mL of a 10% Na2CO3 solution. The solution was stirred until gas evolution was 
complete. The solid was isolated by filtration and washed with water (3 x 50 mL). The 
crude product was recrystallized with methanol and water to produce the final product 
(1.345 g, 85% yield). Spectral data matched reported values.65 
1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.85 
(d, J = 7.9 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 6.74 (d, J = 8.2 
Hz, 2H). 
 
13C NMR (101 MHz, CDCl3) δ 149.36, 129.26, 126.16, 124.55, 122.41, 121.43, 
114.79. 
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Spectrum 17 – 1H NMR of Compound 7 
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Spectrum 18 – 13C NMR of Compound 7 
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Synthesis of Thioflavin Probe (8) 
 
4-Aminobenzothiazole (0.226 g, 1.0 mmol) was dissolved in anhydrous methylene 
chloride (10 mL) containing diisopropylethylamine (166 µL, 0.95 mmol) and sebacoyl 
chloride (102 µL, 0.47 mmol). The reaction stirred at 35°C overnight and monitored by 
TLC. Once complete, the suspension was centrifuged and the supernatant was 
discarded. The pellet was re-dissolved with methylene chloride and centrifuged again, 
twice, to produce a green solid (287.8 mg, 98% yield). Spectral data matched reported 
values.68 
 
1H NMR (400 MHz, DMSO-d6) δ 10.20 (s, 2H), 8.11 (m, J = 8.0 Hz, 2H), 8.02 (m, J 
= 7.3 Hz, 6H), 7.80 (d, J = 8.4 Hz, 4H), 7.52 (t, J = 7.7 Hz, 2H), 7.43 (t, J = 7.6 Hz, 
2H), 2.35 (t, J = 7.5 Hz, 4H), 1.67 – 1.55 (m, 4H), 1.38 – 1.28 (m, 8H). 
 
13C NMR (101 MHz, DMSO-d6) δ 172.23, 167.48, 154.11, 142.65, 134.72, 128.46, 
127.77, 127.02, 125.68, 123.01, 122.71, 119.65, 36.97, 29.15, 29.09, 25.45.  
 
LRMS ESI (m/z): [M+] calculated for C36H34N4O2S2 619.0, observed 619.0. 
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Spectrum 19 – 1H NMR of Compound 8 
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Spectrum 20 – 13C NMR of Compound 8  
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Synthesis of pseudo-rotaxanes using cucurbit[n]uril and bars 
Cucurbit[n]uril (n=6, 7, 8) was dissolved in deuterium oxide at 85oC with the following 
equivalents of different bars. 1H-NMR was performed to see the peak movement of the 
bar when the inclusion complex was formed. Stacked plots are given below. CB [6], CB 
[7] and CB [8] are partially water soluble, once the guest is added, the complex becomes 
clear and homogeneous. 
20 mg (0.020 mmol) of CB [6] + 30 mg (0.114 mmol) of C5 diethylimidazolium bar (2) 
+ 30 ml of DI water (Pseudo-rotaxane 1) 
20 mg (0.020 mmol) of CB [6] + 40 mg (0.131 mmol) of C8 diethylimidazolium bar (3) 
+ 20 ml of DI water (Pseudo-rotaxane 2) 
50 mg (0.050 mmol) of CB [6] + 160 mg (0.481 mmol) of C10 diethylimidazolium bar 
(1) + 80 ml of DI water (Pseudo-rotaxane 3) 
15 mg (0.013 mmol) of CB [7] + 35 mg (0.115mmol) of C8 diethylimidazolium bar (3) 
+ 12 ml of DI water (Pseudo-rotaxane 4) 
15 mg (0.013 mmol) of CB [7] + 30 mg (0.090 mmol) of C10 diethylimidazolium bar 
(1) + 12 ml of DI water (Pseudo-rotaxane 5) 
8.1 mg (0.006 mmol) of CB [8] + 17.6 mg (0.058 mmol) of C8 diethylimidazolium bar 
(3) + 12 ml of DI water (Pseudo-rotaxane 6) 
8.1 mg (0.006 mmol) of CB [8] + 17.6 mg (0.053 mmol) of C10 diethylimidazolium bar 
(1) + 12 ml of DI water (Pseudo-rotaxane 7) 
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Spectrum 21 – 1H NMR of Pseudo-rotaxane 1  
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Spectrum 22 – 1H NMR (Magnified) of Pseudo-rotaxane 1 in the region of guest proton 
resonances  
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Spectrum 23 – 1H NMR of Pseudo-rotaxane 2  
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Spectrum 24 – 1H NMR (magnified) of Pseudo-rotaxane 2 in the region of the guest 
proton resonances 
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Spectrum 25 – 1H NMR of Pseudo-rotaxane 3  
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Spectrum 26 – 1H NMR (magnified) of Pseudo-rotaxane 3 in the region of guest proton 
resonances 
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Spectrum 27 – 1H NMR of Pseudo-rotaxane 4  
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Spectrum 28 – 1H NMR (magnified) of Pseudo-rotaxane 4 in the region of guest proton 
resonances  
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Spectrum 29 – 1H NMR of Pseudo-rotaxane 5  
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Spectrum 30 – 1H NMR (magnified) of Pseudo-rotaxane 5 in the region of guest proton 
resonances  
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Spectrum 31 – 1H NMR of Pseudo-rotaxane 6  
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Representative synthesis of pseudo-rotaxanes using decadimethoxy-
pillar[5]arene, decadibromoethoxy-pillar[5]arene and bars 
 
Decadibromomethoxy-pillar-5-arene (Br-P-5-A) (25 mg, 0.015 mmol) and the 1,10-
diazidodecane bar (5) (3 µL, 0.015 mmol) were dissolved in CDCl3. The sample was 
mixed at room temp for 2hr, 60 °C for 2hr, then an additional 2 hr at 60 °C (total of 4hr 
at 60 °C) to thread the C10 diazide bar (5) into decadibromoethxy-pillar[5]arene. At each 
time interval, a 1H-NMR was taken to observe any chemical shifts. 1H-NMR stacked 
spectrum is shown below.  
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Spectrum 32 – 1H NMR of Br-P-5-A and 5   
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Synthesis of pseudo-rotaxanes using alpha, beta, gamma cyclodextrin and bars 
Cyclodextrin (alpha, beta and gamma) was dissolved in deuterium oxide at 40oC with 
following equivalents with different bars. 1H-NMR was performed to see the peak 
movement of the bar and the peak movement of cyclodextrin and bars (specifically H-
1 proton, H-3 proton of CD and bar protons) when the inclusion complex was formed. 
Stacked plots are given below. 
Alpha CD (31.10 mg, 0.032 mmol) + (2) C5 diethylimidazolium bar (40.50 mg, 0.154 
mmol) in 3 ml of D2O (Pseudo-rotaxane 10) 
Alpha CD (31.10 mg, 0.032 mmol) + (3) C8 diethylimidazolium bar (44.60 mg, 0.146 
mmol) in 3 ml of D2O (Pseudo-rotaxane 11) 
Alpha CD (31.10 mg, 0.032 mmol) + (1) C10 diethylimidazolium bar (47.30 mg, 0.142 
mmol) in 3 ml of D2O (Pseudo-rotaxane 12) 
Beta CD (45.40 mg, 0.040mmol) + (2) C5 diethylimidazolium bar (50.70 mg, 0.193 
mmol) in 6 ml of D2O (Pseudo-rotaxane 13) 
Beta CD (45.40 mg, 0.040 mmol) + (3) C8 diethylimidazolium bar (55.70 mg, 0.183 
mmol) in 6 ml of D2O (Pseudo-rotaxane 14) 
Beta CD (45.40 mg, 0.040 mmol) + (1) C10 diethylimidazolium bar (59.10 mg, 0.178 
mmol) in 6 ml of D2O (Pseudo-rotaxane 15) 
Gamma CD (51.90 mg, 0.040 mmol) + (2) C5 diethylimidazolium bar (50.70 mg, 0.193 
mmol) in 3 ml of D2O (Pseudo-rotaxane 16) 
Gamma CD (51.90 mg, 0.040 mmol) + (3) C8 diethylimidazolium bar (55.70 mg, 0.183 
mmol) in 3 ml of D2O (Pseudo-rotaxane 17) 
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Gamma CD (51.90 mg, 0.040 mmol) + (1) C10 diethylimidazolium bar (59.10 mg, 0.178 
mmol) in 3 ml of D2O (Pseudo-rotaxane 18) 
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Spcetrum 33 – 1H NMR of Pseudo-rotaxane 10  
   
76 
 
 
Spectrum 34 – 1H NMR (magnified) of Pseudo-rotaxane 10 in the region of H-3   
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Spectrum 35 – 1H NMR of Pseudo-rotaxane 11  
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Spectrum 36 – 1H NMR (magnified) of Pseudo-rotaxane 11 in the region of guest proton 
resonances  
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Spectrum 37 – 1H NMR of Pseudo-rotaxane 12  
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Spectrum 38 – 1H NMR of Pseudo-rotaxane 13  
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Spectrum 39 – 1H NMR (magnified) of Pseudo-rotaxane 13 in the region of guest proton 
resonances  
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Spectrum 40 – 1H NMR of Pseudo-rotaxane 14  
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Spectrum 41 – 1H NMR of Pseudo-rotaxane 15  
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Spectrum 42 – 1H NMR (magnified) of Pseudo-rotaxane 15 in the region of guest proton 
resonances  
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Spectrum 43 – 1H NMR of Pseudo-rotaxane 16  
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Spectrum 44 – 1H NMR (magnified) of Pseudo-rotaxane 16 in the region of guest proton 
resonances  
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Spectrum 45 – 1H NMR of Pseudo-rotaxane 17  
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Spectrum 46 – 1H NMR (magnified) of Pseudo-rotaxane 17 in the region of guest proton 
resonances  
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Spectrum 47 – 1H NMR (magnified) of Pseudo-rotaxane 17 in the region of H-3 proton 
of γ-CD  
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Spectrum 48 – 1H NMR of Pseudo-rotaxane 18  
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Spectrum 49 – 1H NMR (magnified) of Pseudo-rotaxane 18 in the region of guest proton 
resonances  
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Spectrum 50 – 1H NMR (magnified) of Pseudo-rotaxane 18 in the region of H-3 proton 
of γ-CD  
   
93 
 
Association studies for Thioflavin-T probe 
 
The NMR titration experiments were conducted per the following procedures. 
The host concentrations were kept constant while the guest concentration was increased 
periodically. Stock solutions of 10 mM host (gamma CD) and 100 mM guest (ThT-
probe) were prepared. A series of NMR samples were prepared ranging from 1:1 (Host: 
guest ratios are mM concentrations) to 1:5, increasing the guest ratio by 1 mM for each 
sample. The aromatic proton of the ThT (circled in red) was monitored. Data was 
processed using Wolfram Mathematica software. The chemical shift values were used 
to determine the correct fit from the equations shown below (Table 2).75 The plots are 
shown below. All samples were prepared at 45 oC. 
 
Table 2: Correct fit equations 
Stoichiometry Equations 
1:1 (equation-1) 
𝑃𝑜𝑏𝑠 =
𝑃𝐺0 + 𝑃𝐺𝐻𝐾11[𝐻]
1 + 𝐾11[𝐻]
 
1:2 (equation-2) 
𝑃𝑜𝑏𝑠 =  
𝑃𝐺0 + 𝑃𝐺𝐻2𝐾12[𝐻]
2
1 + 𝐾12[𝐻]2
 
1:1+1:2 (equation-3) 
𝑃𝑜𝑏𝑠 =
𝑃𝐺0 + 𝑃𝐺𝐻𝐾11[𝐻] +  𝑃𝐺𝐻2𝐾11𝐾12[𝐻]
2
1 + 𝐾11[𝐻] + 𝐾11𝐾12[𝐻]2
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In these equations G and H represent host and guest. PGo and PGH are constants. 
Pobs (NMR shift value) is the y-axis, and the guest concentration is used as the x-axis to 
plot the data. Curve fitting Equation 3 produced a negative value indicating the data set 
does fit the given equation; hence, the combination of 1:1 and 1:2 stoichiometry won’t 
be present in that system. Using the calculated values, the association constants of the 
complexes were obtained. 
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Spectrum 51 – 1H NMR of ThT Probe with Gamma CD in the region of the aromatic 
protons of ThT   
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Spectrum 52 – Date fit for Equation-1; γ-CD and ThT-Probe 
K11 (association constant for 1:1 inclusion complex) = 2 x10
4 M-1  
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Spectrum 53 – Data fit for Equation-2; γ-CD and ThT-Probe 
 K12 (association constant for 1:2 inclusion complex) = 25.6 M
-1  
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Synthesis of Disuccinimidyl Sebacate (9) 
 
Sebacic acid (1.01 g, 5 mmol) was dissolved in dry THF (15 mL). DCC (2.48 g, 12 
mmol) and N-hydroxysuccinimide (1.38 g, 12 mmol) were dissolved in THF (5 mL) 
then added to the reaction at 0 °C. The mixture was stirred for 15 minutes then DMAP 
(73.3 mg, 0.6 mmol) was added. The solution warmed to room temperature and was 
stirred overnight. The white precipitate was filtered, and the solvent was removed from 
the filtrate using vacuum. The crude mixture was dissolved in methylene chloride 
(25mL) and washed with water (3 x 50 mL). The organic layer was dried with Mg2SO4, 
filtered and removed solvent. The crude product was purified using column 
chromatography (hexane:ethyl acetate) to produce a white solid (940 mg, 47% yield). 
Spectral data matched the reported values.67 
1H NMR (400 MHz, DMSO-d6) δ 2.81 (s, 8H), 2.65 (t, J = 7.2 Hz, 4H), 1.62 (p, J = 
7.2 Hz, 4H), 1.40 – 1.25 (m, 8H).  
 
13C NMR (101 MHz, DMSO-d6) δ 170.72, 169.44, 30.64, 28.71, 28.35, 25.91, 24.69. 
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Spectrum 54 – 1H NMR of Compound 9 
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Spectrum 55 – 13C NMR of Compound 9 
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Synthesis of Propargylated ThT (10) 
 
4-aminobenzothiazole (142 mg, 0.626 mmol) was dissolved in dry acetone (10 mL) 
along with K2CO3 (461 mg, 3.337 mmol). The mixture was allowed to reflux for 30 
minutes. Next, KI (104 mg, 0.626 mmol) and propargyl bromide (67 µL, 0.751 mmol) 
was added. The reaction continued to reflux for 24 hrs. Once complete, the mixture was 
allowed to cool then filtered. The solvent was removed under vacuum. The product was 
purified using column chromatography (70:1, methylene chloride:methanol) to produce 
a yellow powder (23 mg, 14% yield). Spectral data matched reported values.66  
1H NMR (400 MHz, DMSO-d6) δ 8.05 (d, J = 7.9 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H), 
7.87 (d, J = 8.4 Hz, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 6.79 (m, J = 
12.2, 7.2 Hz, 3H), 3.98 (dd, J = 6.3, 2.3 Hz, 2H), 3.15 (t, J = 2.6 Hz, 1H).  
 
13C NMR (101 MHz, DMSO-d6) δ 168.38, 154.33, 151.07, 134.28, 129.01, 126.75, 
124.95, 122.42, 122.36, 121.58, 113.10, 81.96, 73.86, 32.19. 
  
  
   
102 
 
 
Spectrum 56 – 1H NMR of Compound 10 
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Spectrum 57 – 13C NMR of Compound 10 
  
   
104 
 
 
BIBLIOGRAPHY 
(1)  Miljani, O.; Dichtel, W. R.; Aprahamian, I.; Rohde, R. D.; Agnew, H. D.; Heath, 
J. R.; Stoddart, J. F. QSAR Comb. Sci. 2007, 26 , 1165–1174. 
(2)  Driehuys, B. Science. 2006, 314, 432–433. 
(3)  Caravan, P.; Ellison, J. J.; Mcmurry, T. J.; Lauffer, R. B. Chem. Rev. 1999, 99, 
2293–2352. 
(4)  Tan, Y.; Hartwig, J. F. J. Am. Chem. Soc. 2010, 132, 3676–3677. 
(5)  Low, P. S.; Henne, W. A.; Doorneweerd, D. D. Acc. Chem. Res. 2008, 41, 120–
129. 
(6)  Hayashi, K.; Moriya, M.; Sakamoto, W.; Yogo, T. Chem. Mater. 2009, 21, 1318–
1325. 
(7)  Zhukova, O. V.; Bulgakova, S. A. Pharm. Chem. J. 2015, 48, 830–834. 
(8)  Happer, W. Rev. Mod. Phys. 1972, 44, 169–240. 
(9)  Albert, M. S.; Cates, G. D.; Driehuys, B.; Happer, W.; Saam, B.; Springer, C. S.; 
Wishnia, A. Nature. 1994, 370, 199–201. 
(10)  Rao, M.; Stewart, N. J.; Norquay, G.; Griffiths, P. D.; Wild, J. M. Magn. Reson. 
Med. 2016, 75, 2227–2234. 
(11)  Mazzanti, M. L.; Walvick, R. P.; Zhou, X.; Sun, Y.; Shah, N.; Mansour, J.; 
Gereige, J.; Albert, M. S. PLoS One 2011, 6, e21607. 
(12)  Hane, F. T.; Imai, H.; Kimura, A.; Fujiwara, H.; Rao, M.; Wild, J. M.; Albert, M. 
S. In Hyperpolarized and Inert Gas MRI: Theory and Applications in Research 
and Medicine; 2016. 
   
105 
 
(13)  Pines, A.; Wemmer, D.; Spence, M.; Rubin, S. M. FUNCTIONALIZED 
ACTIVE-NUCLEUS COMPLEX SENSOR. US 20040062715A1, 2004. 
(14)  Spence, M.; Rubin, S.; Dimitrov, I.; Ruiz, E.; Wemmer, D.; Pines, A.; Yao, S.; 
Tian, F.; Schultz, P. Proc. Natl. Acad. Sci. 2001, 98, 10654–10657. 
(15)  Schröder, L. In Hyperpolarized and inert gas MRI: From technology to 
application in research and medicine; Albert, M. S., Hane, F. T., Eds.; 2016. 
(16)  Schröder, L.; Lowery, T.; Hilty, C.; Wemmer, D.; Pines, A. Science. 2006, 314, 
446–449. 
(17)  Hane, F. T.; Li, T.; Smylie, P.; Pellizzari, R. M.; Plata, J. A.; DeBoef, B.; Albert, 
M. S. Sci. Rep. 2016, in press. 
(18)  Chaffee, K. E.; Fogarty, H. a.; Brotin, T.; Goodson, B. M.; Dutasta, J.-P. P. J. 
Phys. Chem. A 2009, 113 (49), 13675–13684. 
(19)  Stevens, T.; Palaniappan, K.; Ramirez, M.; Francis, M.; Wemmer, D.; Pines, A. 
Magn. Reson. Med. 2013, 69, 1245–1252. 
(20)  Mynar, J. L.; Lowery, T. J.; Wemmer, D. E.; Pines, A.; Fréchet, J. M. J. J. Am. 
Chem. Soc. 2006, 128, 6334–6335. 
(21)  Bai, Y.; Hill, P. A.; Dmochowski, I. J. Anal. Chem. 2012, 84, 9935–9941. 
(22)  Wang, Y.; Dmochowski, I. Chem. Commun. 2015, 51, 8982–8985. 
(23)  Schnurr, M.; Sloniec-Myszk, J.; Döpfert, J.; Schröder, L.; Hennig, A. Angew. 
Chem. Int. Ed. Engl. 2015, 54, 13444–13447. 
(24)  Hane, F.; Smylie, P.; Li, T.; Ruberto, J.; Dowhos, K.; Ball, I.; Tomanek, B.; 
DeBoef, B.; Albert, M. Contrast Media Mol. Imaging 2016, 11, 285–290. 
(25)  Aime, S.; Delli Castelli, D.; Terreno, E.; Transfer, S.; Using, A. Angew. Chem. 
   
106 
 
Int. Ed. 2005, 44, 5513–5515. 
(26)  Stevens, T. K.; Ramirez, R. M.; Pines, A. J. Am. Chem. Soc. 2013, 135, 9576–
9579. 
(27)  Shapiro, M. G.; Ramirez, R. M.; Sperling, L. J.; Sun, G.; Sun, J.; Pines, A.; 
Schaffer, D. V; Bajaj, V. S. Nat. Chem. 2014, 6, 629–634. 
(28)  Bai, Y.; Wang, Y.; Goulian, M.; Driks, A.; Dmochowski, I. J. Chem. Sci. 2014, 
5, 3197–3203. 
(29)  Wang, Y.; Roose, B. W.; Philbin, J. P.; Doman, J. L.; Dmochowski, I. J. Angew. 
Chemie. 2015, 55, 1733. 
(30)  Riggle, B. A.; Wang, Y.; Dmochowski, I. J. J. Am. Chem. Soc. 2015, 137, 5542–
5548. 
(31)  Seward, G. K.; Bai, Y.; Khan, N. S.; Dmochowski, I. J. Chem. Sci. 2011, 2, 1103–
1110. 
(32)  Rose, H. M.; Witte, C.; Rossella, F.; Klippel, S.; Freund, C.; Schröder, L. Proc. 
Natl. Acad. Sci. 2014, 111, 11697–11702. 
(33)  Kotera, N.; Tassali, N.; Léonce, E.; Boutin, C.; Berthault, P.; Brotin, T.; Dutasta, 
J. P.; Delacour, L.; Traoré, T.; Buisson, D. A.; Taran, F.; Coudert, S.; Rousseau, 
B. Angew. Chemie - Int. Ed. 2012, 51, 4100–4103. 
(34)  Tassali, N.; Kotera, N.; Boulard, Y.; Rousseau, B.; Dubost, E.; Brotin, T.; 
Dutasta, J.; Berthault, P. Anal. Chem. 2014, 86, 1783−1788. 
(35)  Dowhos, K. M.; Fox, M. S.; Ball, I. K.; Li, T.; Gajawada, G.; Wentzell, J.; 
DeBoef, B.; Albert, M. S. In International Society for Magnetic Resonance in 
Medicine Annual Meeting; 2014; p 3537. 
   
107 
 
(36)  Khan, N. S.; Riggle, B. A.; Seward, G. K.; Bai, Y.; Dmochowski, I. J. Bioconjug. 
Chem. 2015, 26, 101–109. 
(37)  Fogarty, H. a.; Berthault, P.; Brotin, T.; Huber, G.; Desvaux, H.; Dutasta, J. P. J. 
Am. Chem. Soc. 2007, 129, 10332–10333. 
(38)  Bartik, K.; Luhmer, M.; Dutasta, J. P.; Collet, A.; Reisse, J. J. Am. Chem. Soc. 
1998, 120, 784–791. 
(39)  El Haouaj, M.; Luhmer, M.; Ko, Y. H.; Kim, K.; Bartik, K. J. Chem. Soc. Perkin 
Trans. 2001, 2, 804–807. 
(40)  Herbstein, F. H. Crystalline Molecular Complexes and Compounds: Structures 
and Principles; Oxford Scholarship, 2005. 
(41)  Adiri, T.; Marciano, D.; Cohen, Y. Chem. Commun. 2013, 49, 7082. 
(42)  Schnurr, M.; Sydow, K.; Rose, H. M.; Dathe, M.; Schröder, L. Adv. Healthc. 
Mater. 2015, 4, 40–45. 
(43)  Klippel, S.; Döpfert, J.; Jayapaul, J.; Kunth, M.; Rossella, F.; Schnurr, M.; Witte, 
C.; Freund, C.; Schröder, L. Angew. Chemie - Int. Ed. 2014, 53, 493–496. 
(44)  Kunth, M.; Witte, C.; Hennig, A.; Schroder, L. Chem. Sci. 2015. 
(45)  Kunth, M.; Witte, C.; Schröder, L. NMR Biomed. 2015, 28, 601–606. 
(46)  Tablet, C.; Matei, I.; Hillebrand, M. Stoichiometry and Research - The 
Importance of Quantity in Biomedicine; 2012. 
(47)  Khurana, R.; Coleman, C.; Ionescu-Zanetti, C.; Carter, S. A.; Krishna, V.; 
Grover, R. K.; Roy, R.; Singh, S. J. Struct. Biol. 2005, 151, 229–238. 
(48)  Taratula, O.; Dmochowski, I. J. Curr. Opin. Chem. Biol. 2010, 14, 97–104. 
(49)  Field, L.D.; Sternhell, S. Kalman, J. R. Oganic Structures from Spectra, 4th ed.; 
   
108 
 
John Wiley & Sons, 2008. 
(50)  Massoud, T. F.; Massoud, T. F.; Gambhir, S. S.; Gambhir, S. S. Genes Dev. 2003, 
17, 545–580. 
(51)  Viale, A.; Aime, S. Curr. Opin. Chem. Biol. 2010, 14, 90–96. 
(52)  Schroder, L. Phys. Medica. 2011, 29, 3–16. 
(53)  Möller, H. E.; Chen, X. J.; Saam, B.; Hagspiel, K. D.; Johnson, G. A.; Altes, T. 
A.; De Lange, E. E.; Kauczor, H. U. Magn. Reson. Med. 2002, 47, 1029–1051. 
(54)  Walker, T. G.; Happer, W. Rev. Mod. Phys. 1997, 69, 629–642. 
(55)  Oros, A.-M.; Shah, N. J. Phys. Med. Biol. Biol. 2004, 49, R105–R153. 
(56)  Schroeder, L. In Hyperpolarized and inert gas MRI: From technology to 
application in research and medicine; Albert, M. S., Hane, F. T., Eds.; 2016. 
(57)  Lowery, T. J.; Hilty, C.; Wemmer, D. E.; Pines, A.; Schroder, L. Science. 2006, 
314, 446–449. 
(58)  Xue, M.; Yang, Y.; Chi, X.; Yan, X.; Huang, F. Chem. Rev. 2015, 115, 7398–
7501. 
(59)  El Pairault, N. €; Barat, R.; Tranoy-Opalinski, I.; Renoux, B.; Thomas, M.; 
Ebastien Papot, S. 2016. 
(60)  Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; 
Yang, F.; Cole, G. Source Sci. New Ser. Mol. Cell. Biol. 1996, 274, 99–102. 
(61)  Huang, X. Amyloid Binding Metal Chelating Agents, 2004. 
(62)  Khachaturian, Z. S. Neurology 1985, 42, 1097–1105. 
(63)  Hudson, S. A.; Ecroyd, H.; Kee, T. W.; Carver, J. A. FEBS J. 2009, 276, 5960–
5972. 
   
109 
 
(64)  Kang, Jie; Lemaire, Hans-George; UNterbeck, Axel; Salmbaum, J. Michael; 
Masters, Colin L.; Grzeschik, Karl-Heinz; Multhaup, Gerd; Beyreuther, Konrad; 
Muller-Hill, B. Nature 1987, 325, 733–736. 
(65)  Jae, S.; Yong, J.; Park, D.; Hoon, J. Med. Chem. Res. 2013, 22, 4263–4268. 
(66)  Maračić, S.; Kraljević, T. G.; Paljetak, H. Č.; Perić, M.; Matijašić, M.; Verbanac, 
D.; Cetina, M.; Raić-Malić, S. Bioorg. Med. Chem. 2015, 23, 7448–7463. 
(67)  Patra, D.; Pagliuca, C.; Subramani, C.; Samanta, B.; Agasti, S. S.; Zainalabdeen, 
N.; Caldwell, S. T.; Cooke, G.; Rotello, V. M. Chem. Commun. 2009, 4248–
4250. 
(68)  Phoon, C. W.; Ng, P. Y.; Ting, A. E.; Yeo, S. L.; Sim, M. M. Bioorg. Medicinal 
Chemistry Letters. 2001, 11, 1647–1650. 
(69)  Thomas, J. R.; Liu, X.; Hergenrother, P. J. J. Am. Chem. Soc. 2005, 127, 12434–
12435. 
(70)  Zhao, N.; Lloyd, G. O.; Scherman, O. A. Chem. Commun. 2012, 48, 3070–3072. 
(71)  Zhao, N.; Lloyd, G. O.; Scherman, O. a. Chem. Commun. 2012, 48, 3070. 
(72)  Tian, Y.-K.; Chen, L.; Tian, Y.-J.; Wang, X.-Y.; Wang, F. Polym. Chem. 2013, 
4 , 453. 
(73)  Ogoshi, T.; Aoki, T.; Kitajima, K.; Fujinami, S.; Yamagishi, T. A.; Nakamoto, 
Y. J. Org. Chem. 2011, 76, 328–331. 
(74)  Yao, Y.; Xue, M.; Chi, X.; Ma, Y.; He, J.; Abliz, Z.; Huang, F. Chem. Commun. 
2012, 48, 6505–6507. 
(75)  Tablet, C.; Matei, I.; Hillebrand, M. In Stoichiometry and Research - The 
Importance of Quantity in Biomedicine; InTech, 2012; pp 47–76. 
   
110 
 
 
